Zymeworks and Innovative Targeting Solutions enter collaboration and license agreement to advance biotherapeutics R&D
![](/46/pdcnewsitem/04/22/54/zymeworks.png)
Collaboration will use HuTARG - a first-in-class protein engineering platform.
Zymeworks and Innovative Targeting Solutions (ITS) have entered into a research collaboration, which will complement Zymeworks’ efforts in the discovery, research, and development of novel biotherapeutics. Under the terms of the collaboration, Zymeworks will in-license and integrate ITS’ proprietary HuTARG platform to help identify and develop therapeutics directed towards challenging disease targets.
Ali Tehrani, President and CEO of Zymeworks, stated: “We view the HuTARG platform as a leading technology for the discovery and generation of therapeutic antibodies. This further strengthens our in-house antibody discovery capabilities and accelerates the development of Zymeworks’ novel bi-specific and multi-functional biologics and drug conjugates.”
HuTARG is a first-in-class protein engineering platform and represents a disruptive technology in the field. It is the first fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination, allowing for the generation and affinity maturation of highly potent protein-based biologics.
Michael Gallo, President of Innovative Targeting Solutions Inc., remarked: “Zymeworks is a leader in the development of innovative biotherapeutics. Together with our first-in-class protein engineering technology, they will be able to discover novel medicines that can transform the lives of people with grievious illnesses.”
Under the agreement, Zymeworks will pay a technology licensing fee to integrate and use the HuTARG platform. In addition, ITS will receive, on a per product basis upon successful development and commercialization, up to $65 million in clinical and commercial milestones and low single-digit royalties on net sales. Additional financial terms have not been disclosed.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance